Abstract
Dry eye disease (DED) is a prevalent disorder of the ocular surface and tear film for which currently no fully satisfactory treatment exists, reflecting its multifactorial nature and perhaps inherent limitations of existing treatments. Responding to this unmet medical need, the research community and pharmaceutical industry display robust activity in the development of novel approaches to DED treatment. These efforts include pharmaceutical agents and devices directed at various pathogenetic aspects of this still incompletely understood disease. Here, we review current and under development treatments and assess the state of this evolving field.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
